08:37 AM EDT, 03/17/2025 (MT Newswires) -- OPKO Health ( OPK ) said Monday it will work with Entera Bio ( ENTX ) to push an oral dual agonist for obesity and related conditions into clinical testing.

The drug combines OPKO's extended-release GLP-1/glucagon analog with Entera's tablet formulation technology, with an FDA filing planned later this year, OPKO said.

Under the agreement, OPKO will cover 60% of development expenses and Entera 40%, with ownership split along the same lines, the companies said.

To help cover its share, Entera said it sold roughly 3.7 million shares to OPKO for $2.17 each. If Entera decides to drop out, it will still retain a 15% stake.

Entera's shares were up more than 10% in recent Monday premarket activity.